Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
（株）ステムリム logo — Pioneering regenerative medicine by harnessing the body's ow...

（株）ステムリム

Pioneering regenerative medicine by harnessing the body's own stem cells to repair and rejuvenate damaged tissues.

Founded 2006 7 employees Venture round Total: $3.45B Biotechnology

General Information

Company Name （株）ステムリム
Founded Year 2006
Employees 7
Industries Biotechnology
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with （株）ステムリム. To contact （株）ステムリム, visit stemrim.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does （株）ステムリム compare?

A PDF of （株）ステムリム and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting （株）ステムリム soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About （株）ステムリム

StemRIM is a pioneering biotechnology company founded in 2006 with a focus on regenerative medicine. Their slogan, "Pioneering regenerative medicine by harnessing the body's own stem cells to repair and rejuvenate damaged tissues," encapsulates their mission. StemRIM is driving innovation by creating drugs with a novel mechanism of action that mobilizes stem cells within the living body to target injured or diseased tissue. This process promotes functional tissue regeneration without the need for extraction. Their last investment was an impressive ¥745.02M Venture Round secured on 28 December 2018. This investment was backed by a consortium of prominent investors including SMBC Venture Capital, KSP, Miyako Capital, Kyogin Lease & Capital, M3i, M3. StemRIM's ongoing dedication to advancing regenerative medicine makes them an exciting prospect for potential investors seeking to tap into the promising biotechnology industry.

Business keywords: Regenerative Medicine, Stem Cells, Tissue Repair, Drug Development, Innovation, Biomedical Technology, Tissue Regeneration, Medical Research, Healthcare Innovation

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round ¥745.02M 6
SMBC Venture Capital KSP Miyako Capital
SMBC Venture Capital, KSP +4
28 Dec 2018
Venture Round ¥699.93M 1
Daiwa Corporate Investment
Daiwa Corporate Investment
07 Dec 2018
Venture Round ¥199.98M 1
Mitsubishi UFJ Capital
Mitsubishi UFJ Capital
15 Dec 2017
Venture Round ¥1.00B 2
Miyako Capital Kyogin Lease & Capital
Miyako Capital, Kyogin Lease & Capital
17 Nov 2017
Corporate Round ¥800.00M -
15 Dec 2014

（株）ステムリム Alternatives & Competitors

View All Alternatives
（株）ステムリム vs
Endogena Therapeutics, Inc.
Endogena Therapeutics, Inc. Switzerland

endogena’s mission is to discover and develop endogenous regenerative medicines to repair and regene...

Series A
4 employees
Biotechnology, Health and Wellness
（株）ステムリム vs
Histocell. Regenerative Medicine
Histocell. Regenerative Medicine Spain

Advanced therapy medicinal products, medical devices and dermocosmetics for regenerative medicine.

Grant
41 employees
Biotechnology, Health Care
（株）ステムリム vs
China Regenerative Medicine International
China Regenerative Medicine International Hong Kong S.a.r.

Pioneering the future of regenerative medicine with advanced gene and stem cell products.

16 employees
Biotechnology, Manufacturing
View all alternatives

FAQ About （株）ステムリム

Pioneering regenerative medicine by harnessing the body's own stem cells to repair and rejuvenate damaged tissues.
（株）ステムリム was founded in 2006.
（株）ステムリム operates in Biotechnology. Its work centres on Regenerative Medicine, Stem Cells, Tissue Repair and Drug Development.
（株）ステムリム has approximately 7 employees.
（株）ステムリム has completed 5 funding rounds, raising a total of $3.45B. The latest funding stage is Venture round.
Top alternatives and competitors to （株）ステムリム include Endogena Therapeutics, Inc., Histocell. Regenerative Medicine, China Regenerative Medicine International, Renovos Biologics Limited, Mesenbio. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
（株）ステムリム and Endogena Therapeutics, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for （株）ステムリム, https://bouncewatch.com/company/stemrim, updated 14 January 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes